Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 2/20 | 0.52 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.52 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.42 |
| ▸ | DRD4 | P21917 | 4/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7923023 | 0.84 | MTOR (0.50) | MTORRPTORMLST8MAP4K4RAB9A | |
| SCHEMBL1002407 | 0.82 | SMN1; SMN2 (0.44) | MTORRPTORMLST8RAB9ANPC1 | |
| SCHEMBL21281739 | 0.82 | SMN1; SMN2 (0.47) | MTORRPTORMLST8RAB9ANPC1 | |
| SCHEMBL18586366 | 0.82 | PTGS2 (0.47) | MTORRPTORMLST8RAB9ANPC1 | |
| SCHEMBL18586388 | 0.82 | ALDH1A1 (0.53) | MTORRPTORMLST8RAB9ANPC1 | |
| SCHEMBL15332503 | 0.82 | ALDH1A1 (0.51) | MTORRPTORMLST8HSD17B10MAP4K4 | |
| SCHEMBL1990298 | 0.82 | MTOR (0.52) | MTORRPTORMLST8RAB9ANPC1 | |
| SCHEMBL70114 | 0.81 | NPC1 (0.63) | MTORRPTORMLST8RAB9ANPC1 | |
| SCHEMBL23036950 | 0.81 | MTOR (0.55) | MTORRPTORMLST8RAB9ANPC1 | |
| SCHEMBL5483638 | 0.81 | NOTUM (0.45) | MTORRPTORMLST8RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215012-A1 | IKZF2 DEGRADERS AND USES THEREOF | UNIV MICHIGAN (US) | 2025-07-03 | — | — | US | disclosed |
| CN-119731179-A | IKZF2 degradation agent and application thereof | 密歇根大学董事会 | 2025-03-28 | — | — | CN | disclosed |
| US-12180189-B2 | Proteostasis regulators | Kineta, Inc. (US) | 2024-12-31 | — | — | US | disclosed |
| CN-112368279-B | Novel compounds as mTOR inhibitors and uses thereof | 医药生命融合研究团 | 2024-05-28 | — | — | CN | disclosed |
| US-11649231-B2 | Compound as mTOR inhibitor and use thereof | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2023-05-16 | — | — | US | disclosed |
| US-20210292314-A1 | NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2021-09-23 | — | — | US | disclosed |
| CN-109689644-B | Pyridazinone compound and application thereof | 沈阳中化农药化工研发有限公司 | 2021-07-30 | — | — | CN | disclosed |
| EP-3786163-A1 | NOVEL COMPOUND AS MTOR INHIBITOR AND USE THEREOF | Medicinal Bioconvergence Research Center (KR) | 2021-03-03 | — | — | EP | disclosed |
| CN-107964007-B | Pyridazinone compound and application thereof | 沈阳中化农药化工研发有限公司 | 2021-02-12 | — | — | CN | disclosed |
| CN-112368279-A | Novel compounds as mTOR inhibitors and uses thereof | 医药生命融合研究团 | 2021-02-12 | — | — | CN | disclosed |
| US-20120316193-A1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. | 2012-12-13 | — | — | US | disclosed |
| US-20120316193-A1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. | 2012-12-13 | — | — | US | disclosed |
| WO-2012154967-A1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012154967-A1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| EP-0691332-B1 | Pyrazolyl derivatives, their preparation and their use as pesticides | BASF AG (DE) | 1999-09-08 | — | — | EP | disclosed |
| US-5506254-A | INSECTICIDE, PESTICIDE, MITICIDES, NEMATOCIDES | BASF AKTIENGESELLSCHAFT (DE) | 1996-04-09 | — | — | US | disclosed |
| EP-0691332-A1 | Pyrazolyl derivatives, their preparation and their use as pesticides | BASF AKTIENGESELLSCHAFT (DE) | 1996-01-10 | — | — | EP | disclosed |
| US-4220792-A | ANTIDIABETIC AGENTS | SANDOZ, INC. (US) | 1980-09-02 | — | — | US | disclosed |
| US-4125530-A | FROM 1,1-DIHALO-3,3,3-TRIFLUOROACETONE, BASE, AMMONIA AND A CARBOXALDEHYDE | MERCK & CO., INC. (US) | 1978-11-14 | — | — | US | disclosed |
| US-4032522-A | ANTI-GOUT, ANTI-HYPERURICEMIC | MERCK & CO., INC. (US) | 1977-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215012-A1 | IKZF2 DEGRADERS AND USES THEREOF | IKZF1, IKZF2, IKZF3 | MTOR 4256/4885RPTOR 3456/4885MLST8 1573/4885 |
| US-11649231-B2 | Compound as mTOR inhibitor and use thereof | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 8/4885 |
| US-12180189-B2 | Proteostasis regulators | PSMG3, VCP, HSPA5 | MTOR 918/4885RPTOR 381/4885MLST8 806/4885 |
| US-20120316193-A1 | PROTEOSTASIS REGULATORS | PSMG3, VCP, HSPA5 | MTOR 918/4885RPTOR 381/4885MLST8 806/4885 |
| US-20210292314-A1 | NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.